Direct Oral Anticoagulants (DOACs) for MPN thromboprophylaxis
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-03-20 — AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms: AVAJAK trial (prospective, trial-early): proposed head-to-head comparison of apixaban or rivaroxaban versus low-dose aspirin for primary thromboprophylaxis in JAK2V617F-positive MPN, the first prospective trial directly addressing DOAC superiority in this population. (novelty: 4) (novelty: 4)
Open questions
Related
Contributing findings
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
20-mar-2026
novelty 4
per-area 4
introduces